Aibotics, Inc. financial data

Symbol
AIBT on OTC
Industry
Medicinal Chemicals & Botanical Products
Location
480 22 Nd Street, Heyburn, ID
State of incorporation
NV
Fiscal year end
December 31
Former names
Mycotopia Therapies, Inc. (to 12/17/2024), 20/20 Global, Inc. (to 5/19/2021)
Latest financial report
10-K - Q4 2024 - Apr 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 5.4 % -59.8%
Debt-to-equity -159 % -5.41%
Return On Equity 60.9 % -17.6%
Return On Assets -104 % +29%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.7M shares +187%
Common Stock, Shares, Outstanding 40M shares +168%
Entity Public Float 1.37M USD -11.5%
Common Stock, Value, Issued 40K USD +168%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 1.63M USD +165%
Operating Income (Loss) -1.63M USD -165%
Nonoperating Income (Expense) -213K USD +62.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.85M USD -56.5%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -1.85M USD -56.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 185K USD -33.7%
Property, Plant and Equipment, Net 0 USD -100%
Assets 1.46M USD -34.4%
Accrued Liabilities, Current 400K USD +66.8%
Liabilities, Current 4.85M USD +14.2%
Liabilities 4.85M USD +14.2%
Retained Earnings (Accumulated Deficit) -10.8M USD -20.6%
Stockholders' Equity Attributable to Parent -3.39M USD -67.4%
Liabilities and Equity 1.46M USD -34.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -73.7K USD -155%
Net Cash Provided by (Used in) Financing Activities 165K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 467M shares +367%
Common Stock, Shares, Issued 40M shares +168%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 185K USD -33.7%
Deferred Tax Assets, Valuation Allowance 993K USD +79.9%
Deferred Tax Assets, Gross 993K USD +79.9%
Depreciation 498 USD -50.1%
Deferred Tax Assets, Operating Loss Carryforwards 442K USD +64.7%
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 7.37M USD +6.6%
Interest Expense 213K USD +37706%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares